Regeneron

News

Black and white image of a child holding a conch to their ear

Evidence builds behind Regeneron's deafness gene therapy

Ten out of 11 children with congenital deafness treated with a gene therapy developed by Regeneron have seen "notable" improvements in hearing.

News

Can Dupixent plug treatment gap in bullous pemphigoid?

The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.

News

Truveta's co-founder and chief executive, Terry Myerson

Regeneron, Illumina join $320m Truveta investment

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

News

Regeneron builds in eye disease tech with Oxular takeover

Regeneron has bought Oxular, a UK specialist in retinal diseases, in a move that bolsters its already strong position in ophthalmology therapies.

News

ASH: Regeneron plays its PNH hand

Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.

News

Closeup of vials on a conveyor at Amgen facility

Legal win leads Amgen to at-risk launch of Eylea biosimilar

Amgen has chalked up a victory in a patent infringement lawsuit with Regeneron over blockbuster ophthalmic drug Eylea and decided to launch its biosimilar in the US – even though the legal

Evidence builds behind Regeneron's deafness gene therapy

Can Dupixent plug treatment gap in bullous pemphigoid?

Regeneron, Illumina join $320m Truveta investment

Regeneron builds in eye disease tech with Oxular takeover

ASH: Regeneron plays its PNH hand

Legal win leads Amgen to at-risk launch of Eylea biosimilar

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Regeneron

Editor's Picks